GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » Cash Ratio

Oxford Immunotec Global (Oxford Immunotec Global) Cash Ratio : 13.61 (As of Sep. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Oxford Immunotec Global's Cash Ratio for the quarter that ended in Sep. 2020 was 13.61.

Oxford Immunotec Global has a Cash Ratio of 13.61. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Oxford Immunotec Global's Cash Ratio or its related term are showing as below:

OXFD's Cash Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.06
* Ranked among companies with meaningful Cash Ratio only.

Oxford Immunotec Global Cash Ratio Historical Data

The historical data trend for Oxford Immunotec Global's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global Cash Ratio Chart

Oxford Immunotec Global Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 5.41 3.20 4.02 10.71 13.12

Oxford Immunotec Global Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.02 13.12 11.86 15.31 13.61

Competitive Comparison of Oxford Immunotec Global's Cash Ratio

For the Diagnostics & Research subindustry, Oxford Immunotec Global's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Immunotec Global's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford Immunotec Global's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Oxford Immunotec Global's Cash Ratio falls into.



Oxford Immunotec Global Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Oxford Immunotec Global's Cash Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash Ratio (A: Dec. 2019 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=181.27/13.819
=13.12

Oxford Immunotec Global's Cash Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash Ratio (Q: Sep. 2020 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=160.621/11.801
=13.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Immunotec Global  (NAS:OXFD) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Oxford Immunotec Global Cash Ratio Related Terms

Thank you for viewing the detailed overview of Oxford Immunotec Global's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Traded in Other Exchanges
N/A
Address
143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE
Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.
Executives
Andrew Scott Walton director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith director, officer: Chief Executive Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn officer: Chief Operating Officer C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd officer: General Counsel C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley officer: SVP & General Counsel C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup officer: Chief Medical Officer C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ

Oxford Immunotec Global (Oxford Immunotec Global) Headlines

From GuruFocus